hydroxyl, halo, C_{1-4} alkyl, aralkyl, aryl, aryloxy, aralkyloxy, acylamino, $-NO_2$, $-S(O)_2R^{26}$, -CN, C_{1-3} alkoxy, $-CF_3$, $-OCF_3$, aryl, heteroaryl and cycloalkyl; and R^{26} and R^{28} are in each instance independently selected from the group consisting of hydrogen, C_{1-4} alkyl, aryl and cycloalkyl; and

wherein the C_{1-4} alkyl, aryl and cycloalkyl may be further substituted with from 1 to 3 substituents independently selected from the group consisting of hydroxyl, halo, C_{1-4} alkoxy, $-CF_3$ and $-OCF_3$;

or a pharmaceutically acceptable salt, ester, hydrate, solvate, stereoisomer, mixture of stereoisomers, tautomer, polymorph and/or prodrug thereof.

60. The compound of claim 59, wherein when Y is -C(O)-, X is -O-, each R^4 is hydrogen, R^2 and R^3 together with the atom to which they are attached form a piperazine which is optionally substituted with tert-butoxycarbonyl and Q is a bond, then R^1 is not unsubstituted phenyl or morpholinyl; and that when Y is $-S(O)_2-$, X is -O-, R^2 is benzyl, each R^3 is hydrogen, Z^4 is C-Q-R^1, Q is a bond and R^1 is aryl or heteroaryl, then both R^4 are hydrogen.

61. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of the compound of any one of claims 1 to 60 or a pharmaceutically acceptable salt, thereof.

62. ~~A method of~~ The use of a compound of any one of claims 1 to 60 in the manufacture of a medicament for treating a disease state in a mammal that is alleviable by treatment with an agent capable of reducing late sodium current~~, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of any one of claims 1 to 60~~.

63. The ~~method~~ use of claim 62, wherein the disease state is a cardiovascular disease selected from one or more of atrial arrhythmias, ventricular arrhythmias, heart failure (including congestive heart failure, diastolic heart failure, systolic heart failure, acute heart failure), Prinzmetal's (variant) angina, stable angina, unstable angina, exercise induced angina, congestive heart disease, ischemia, recurrent ischemia, reperfusion injury, myocardial infarction, acute coronary syndrome, peripheral arterial disease, pulmonary hypertension and intermittent claudication.

64. The ~~method~~ use of claim 62, wherein the disease state is diabetes or diabetic peripheral neuropathy.

65. The ~~method~~ use of claim 62, wherein the disease state results in one or more of neuropathic pain, epilepsy, migraine, seizures or paralysis.

66. ~~Use of a~~A compound according to any one of claims 1 to 60 for use in therapy.

67. Use of a compound according to any one of claims 1 to 60 in the manufacture of a medicament for treating one or more diseases selected from atrial arrhythmias, ventricular arrhythmias, heart failure (including congestive heart failure, diastolic heart failure, systolic heart failure, acute heart failure), Prinzmetal's (variant) angina, stable angina, unstable angina, exercise induced angina, congestive heart disease, ischemia, recurrent ischemia, reperfusion injury, myocardial infarction, acute coronary syndrome, peripheral arterial disease, pulmonary hypertension and intermittent claudication.